HC Wainwright & Co. Reiterates Buy on ASLAN Pharma, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on ASLAN Pharma (NASDAQ:ASLN) and maintained a $9 price target.
April 23, 2024 | 10:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on ASLAN Pharma with a $9 price target, indicating a positive outlook on the stock.
The reiteration of a Buy rating and maintenance of a $9 price target by a reputable analyst suggests a strong belief in ASLAN Pharma's potential for growth. This endorsement could positively influence investor sentiment and potentially drive up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100